Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

AIM ImmunoTech Inc

AIM
0,42
-0,0051 (-1,20%)
Ultimo aggiornamento: 17:07:46
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/6/202414:55GLOBEAIM ImmunoTech to Participate in the Virtual Investor Pitch..
03/6/202416:15EDGAR2Form 8-K - Current report
03/6/202416:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/6/202415:15GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
31/5/202414:30GLOBEAIM ImmunoTech Announces Pricing of $2.0 Million Registered..
31/5/202414:14EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/5/202415:15GLOBEAIM ImmunoTech to Participate in Two Upcoming Investor..
16/5/202413:30GLOBEAIM ImmunoTech Reports First Quarter 2024 Financial Results..
15/5/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202414:50GLOBEAIM ImmunoTech to Discuss First Quarter 2024 Financial..
07/5/202414:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202414:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202414:30GLOBEAIM ImmunoTech Completes cGMP Manufacturing of Clinical..
29/4/202414:55GLOBEAIM ImmunoTech Announces First Dose Level is Generally..
25/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
18/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/4/202414:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
11/4/202417:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
10/4/202414:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
02/4/202413:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
28/3/202413:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
26/3/202414:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
25/3/202414:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
22/3/202413:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
20/3/202414:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/3/202413:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
07/3/202414:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
29/2/202414:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
21/2/202416:37EDGAR2Form D/A - Notice of Exempt Offering of Securities: [Amend]
20/2/202422:31EDGAR2Form 8-K - Current report
14/2/202414:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
09/2/202421:47EDGAR2Form 8-K - Current report
08/2/202414:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
25/1/202423:00EDGAR2Form 8-K - Current report
24/1/202415:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
22/1/202414:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
10/1/202419:42EDGAR2Form 8-K - Current report
10/1/202414:45EDGAR2Form 8-K - Current report
10/1/202414:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
05/1/202419:32BWAIM Shareholders Elect All Four Company Director Nominees at..
03/1/202422:24EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202422:24EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
03/1/202422:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
29/12/202314:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/12/202314:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
28/11/202322:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/11/202322:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202318:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
Apertura: 0,4267 Min: 0,4119 Max: 0,4267
Chiusura: 0,4251

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network